Company intelligence / Profile preview

Dual Therapeutics

South San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Dualitas has developed a proprietary DualScreen platform that screens 100,000+ unique bispecific combinations to identify synergistic cell-surface proximity mechanisms. Lead programs DTX-102 (autoimmune) and DTX-103 (allergic disease) have demonstrated differentiated preclinical profiles compared to available therapies, with enhanced potency and efficacy beyond competitive inhibition.

Therapeutic areas: ImmunologyGastroenterology
Modalities: Bispecific monoclonal antibody
Industry: Biotech

Drug pipeline

2 assets

DT-061

Preclinical

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Dual Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dual Therapeutics.

Explore the full profile